Promote the infiltration of CD4+ and CD8+T cells into the tumor microenvironment, and at the same time reverse the resistance of B16 melanoma to anti-PD-1 treatment alone, enabling the combined treatment to significantly inhibit tumor growth and prolong the survival period of mice [108]. The gene discussed is CD8A; the disease is neoplasm.